Overview

Vopratelimab (JTX-2011) Alone and in Combination With Anti-PD-1 or Anti-CTLA-4 in Subjects With Advanced and/or Refractory Solid Tumors

Status:
Recruiting

Trial end date:
2024-07-31

Target enrollment:

Participant gender:

Summary

JTX-2011-R01 is an open label, multicenter, rollover study that is designed to provide continued access to vopratelimab for eligible subjects with advanced solid tumor malignancies who have previously participated in a vopratelimab study (the parent study).

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Jounce Therapeutics, Inc.

Treatments:

Ipilimumab
Nivolumab